Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Incyte_Corporation
|
| gptkbp:activities |
FGFR inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase 2
NC T02964818 NC T03319711 NC T03319724 NC T02964805 NC T02964831 NC T03057013 NC T03057026 NC T03621185 NC T03621191 NC T03621198 |
| gptkbp:contraindication |
pregnancy
severe hepatic impairment lactation |
| gptkbp:developed_by |
gptkb:Incyte_Corporation
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
April 17, 2020
|
| gptkbp:has_ability |
4.5 mg
9 mg 13.5 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Pemigatinib
|
| gptkbp:indication |
intrahepatic cholangiocarcinoma
FGF R2 fusion-positive cholangiocarcinoma FGF R2 rearrangement-positive cholangiocarcinoma |
| gptkbp:ingredients |
C22 H22 N4 O3 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors other FGFR inhibitors |
| gptkbp:invention |
patented
|
| gptkbp:is_used_for |
treatment of cholangiocarcinoma
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
brand name Pemazyre
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea decreased appetite diarrhea rash dry mouth thrombocytopenia elevated liver enzymes hyperphosphatemia |
| gptkbp:targets |
FGF R2
|